| Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain (NCT07624838) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2026-02-15 |
| Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma (NCT07285590) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2025-09-30 |
| Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma (NCT07126236) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2025-08-04 |
| Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma (NCT07254754) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2024-11-20 |
| BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (NCT04378647) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2020-06-01 |
| BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) (NCT03576378) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2018-08-08 |
| DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB (NCT04244331) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2018-05-01 |
| Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL (NCT02682641) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2016-05-18 |
| Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT (NCT02692248) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2016-04-07 |
| Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT (NCT02267915) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2015-03-01 |
| Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma (NCT02243436) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2014-11-11 |
| Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb (NCT02012088) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2013-10-11 |
| Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. (NCT01848132) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2013-10-03 |
| Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients (NCT01613300) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2012-04-04 |
| Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). (NCT01296256) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-05-01 |
| Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL (NCT01562977) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-04-01 |
| Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma (NCT02340936) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-01-01 |
| Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma (NCT01195766) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2010-07-01 |
| R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial (NCT01133158) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2009-07-01 |
| Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (NCT01015248) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2009-05-01 |
| Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma (NCT01369784) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2009-02-01 |
| Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom (NCT00646750) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2008-01-01 |
| Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) (NCT00644371) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2007-11-01 |
| Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (NCT01361191) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2007-06-01 |
| Cyclosporine Plus Methotrexate or Alemtuzumab (NCT02701517) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2003-09-01 |